The mutation frequencies of a consecutive population-based Swedish cohort have been proven to be similar to those observed in other Western populations, except for a notable high frequency (43%) of activating KRAS mutations among patients with lung adenocarcinoma [8]. The gene discussed is KRAS; the disease is lung adenocarcinoma.